Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Uterine sarcoma, drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Preoperative distinction of leiomyosarcoma from fibroids: MRI and LDH criteria and imaging AI are under study.
Advanced LMS remains chemoresistant after two lines: PARP inhibitors for the HRD subset and antibody-drug conjugates are in trials.
High-grade ESS and undifferentiated sarcoma have no proven standard beyond anthracycline.
Rarity limits randomised evidence: international sarcoma consortia are pooling trials.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
Median PFS 12.
Pautier and colleagues, Lancet Oncol.
NTRK fusion-positive solid tumours, including colorectal cancer
NTRK fusion-positive solid tumours in adults and children, locally advanced or metastatic or where surgery would cause severe morbidity, with no satisfactory treatment options: NICE TA630 (27 May 2020) recommends it within the Cancer Drugs Fund under a managed access agreement
Adjuvant chemotherapy for stage I LMS did not improve outcomes; observation is standard.